Life Insurance Quotes

Study shows treatment reduces condition associated with Alzheimer’s

10/13/11

According to a recent report that appeared in Archives of Neurology, one of the JAMA/Archives journals, Alzheimer’s patients who were treated with the medication gantenerumab saw a reduction in their brain amyloid levels.

"Genetic and neuropathological evidence suggests that the accumulation of amyloid-β (Aβ) peptides in the brain is a key event in the pathophysiology of Alzheimer disease (AD)," the authors stated.

Amyloids are insoluble fibrous protein aggregates that share specific structural traits. The study concluded that two to seven months of dose-dependent treatment with gantenerumab could lead to the reduction of amyloid in the brain. The author suggested the treatment may work through an "effector cell-mediated mechanism of action."

The research is still unclear if any reduction in brain amyloid levels will result in clinical efficacy, which has resulted in a second phase of treatment.

Alzheimer’s is the leading cause of long-term care insurance benefit payments, according to the American Association for Long-Term Care Insurance, and there are more than 5 million cases of Alzheimer’s disease in the United States. Statistics show that 2 to 4 percent of the population over 65 will have Alzheimer’s, causing a need for adequate life insurance among Americans and further research of this condition.  

Talk to an Advisor

A licensed insurance advisor can explain your options and help you choose the right life insurance for your needs.

Call: 1-800-823-4852

Chat: Live Advisor Chat

Sm

A few of the carriers we quote